Kornimate/medical-research-clean huggingface dataset:
accuracy of teledentistry versus direct oral examination for elderly in aged-care homes: a pilot cross-sectional study

Conditions: Oral Screening for Elderly in Aged Care Homes

Summary: the residents will receive oral health education, then three examiners ( licensed dentists ) will perform the direct oral examination of the participants. during the same visit, a dental student will take the intraoral photographs in the aged care home. later, three different blinded examiners (licensed dentists) will assess the intraoral photographs of the same group of participants. the participant's dentition will be examined using the scores developed by the world health organization (who) for oral health surveys. also, the examiners will perform a visual inspection of the oral mucosa for any signs of oral potentially malignant disorders (opmd), as the mortality of high-risk populations is proven to be reduced by visual oral cancer screening. finally, the residents who require treatment will be referred to kasr el ainy dental hospital to receive dental treatments.

the residents will receive oral health education, by three examiners ( licensed dentists ) with a t least 5 years experience. then the same examiner will perform the direct oral examination of the participants. they will fill the dentition status, denture status, oral lesions and intervention urgency section of the world health organization (who) form 2013 version. during the same visit, a dental student will take the intraoral photographs in the aged care home. the photographs will include 5 views (upper occlusal, lower occlusal , frontal, right lateral and left lateral). the photographs will be uploaded on one drive and later, three different blinded examiners (licensed dentists) will assess the intraoral photographs of the same group of participants. the participant's dentition will be examined using the scores developed by the world health organization (who) for oral health surveys. also, the examiners will perform a visual inspection of the oral mucosa for any signs of oral potentially malignant disorders (opmd), as the mortality of high-risk populations is proven to be reduced by visual oral cancer screening. finally, the residents who require treatment will be referred to kasr el ainy dental hospital to receive dental treatments.

Eligibility criteria:
inclusion criteria: * elderly living in aged care homes in egypt * have the ability to communicate with the examiner * have the ability to give consent to participate in the study.
remote ischemic conditioning and platelet dysfunction

Conditions: Platelet Function

Summary: the purpose of this study is to evaluate the effects of remote ischemic conditioning on platelet function during off-pump coronary artery bypass surgery.

remote ischemic conditioning (ric) may affect platelet function. however, little is known about effect of ric on platelet function during off-pump coronary artery bypass surgery. in this study investigators are going to perform ric after anesthesia induction (remote ischemic pre-conditioning) and after completion of coronary anastomoses (remote ischemic post-conditioning), and compare platelet function parameters with control group.

Eligibility criteria:
inclusion criteria: * 20 - 80 years of adult patient undergoing elective off-pump coronary artery bypass surgery exclusion criteria: * acute myocardial infarction * recent (\<1 month) coronary angioplasty (percutaneous coronary intervention, pci) * acute cerebrovascular ischemia (\<6 months) * preoperative lv ef \< 30%, mechanical ventricular support (iabp, vad, ecmo) * peripheral vascular disease * poorly controlled diabetes mellitus * alzheimer's disease * nsaids within 3 days * iv heparin within 6 h * low molecular weight heparin within 24 h * platelet inhibitor within 24 h * known thrombocytopenia * renal failure / hemodialysis * active infection * preoperative bleeding diathesis * redo-operation * pregnancy

Keywords: remote ischemic conditioning off-pump coronary artery bypass surgery
oral manifestation of covid 19 patient: a cross sectional study on egyptian population

Conditions: Oral Health and COVID 19

Summary: the oral manifestation of covid 19 that could help in the diagnosis of patient

oral ulceration,oral lesion,sensitivity that has been reported by patient tested positive for covid 19

Eligibility criteria:
inclusion criteria: * tested covid positive * no other chronic disease that has oral manifestation * above 18 exclusion criteria: * children * patient with no covid positive
chronic effects of fats on satiety & energy needs

Conditions: Overweight; Obesity

Summary: the purpose of this study is to evaluate the effect of dietary fat on satiety (the experience of fullness between one meal and the next) and energy metabolism over an extended period of time (chronic effects). how dietary fat sources affect satiety, appetite and energy use is unclear. the investigators will use a controlled setting for the studies. they want to know if the source of dietary fat alters satiety, satiety hormones, and energy expenditure responses after consuming different diets.

this work will address the interaction of obesity and dietary fatty acids in regulating satiety and energy metabolism. the primary objective is to determine the effects of chronic intake of dietary fatty acids of varied saturation and chain length on satiety, thermogenesis and energy utilization in healthy individuals. the investigators hypothesize that unsaturated fatty acids will 1) increase satiety and 2) increase energy metabolism and that 3) the fatty acid binding protein polymorphisms are associated with reduced energy expenditure in response to dietary fat intake.

Eligibility criteria:
inclusion criteria: * body mass index between 25.0-34.9 kg/m2 * free of major diagnosed, untreated medical conditions * non-smoking or use of other tobacco products, including e-cigarettes * not taking steroid-based medications * not planning to or currently attempting to gain or lose weight * willing to comply with study demands * low intake of long chain omega-3 fatty acids (\<0.10 g/d) or willing to reduce intake for 6 weeks prior to starting the study exclusion criteria: * diagnosed eating disorders * diabetes (blood sugar ≥ 126 mg/dl) * hypertension (systolic \> 160 mmhg or diastolic \> 100 mmhg) * diagnosed cardiovascular, pulmonary, skeletal and metabolic diseases * currently pregnant or planning to become pregnant, or lactating * taking medications known to affect appetite, blood lipids, body composition, body weight, or food intake (appetite control drugs, steroids, antidepressants)

Keywords: energy expenditure appetite satiety
continuous wireless monitoring of vital signs and automated alerts of patient deterioration in patients admitted with covid-19 infection

Conditions: Clinical Deterioration

Summary: for patients admitted with covid-19 infection, it is often difficult to predict if or when their clinical condition will deteriorate. however subtle changes in vital signs are usually present 8 to 24 hours before a life-threatening event such as respiratory failure leading to icu admission, or unanticipated cardiac arrest. such adverse trends in clinical observations can be missed, misinterpreted or not appreciated as urgent. new continuous and wearable 24/7 clinical vital parameter monitoring systems offer a unique possibility to identify clinical deterioration before patients condition progress beyond the point-of-no-return, where adverse events are inevitable. the primary aim of this study is to test the effect of continuous wireless vital signs monitoring with generation of real-time alerts through a purpose-built gui, compared to standard ews monitoring on the cumulative duration of any severely deviating vital signs


Eligibility criteria:
inclusion criteria * adult patients (≥18 years). * inclusion possible within 72 hours of admission, or within 48 hours of discharge from an icu to a medical ward * at least one expected overnight stay. * patient admitted with confirmed covid-19 infection exclusion criteria * patient expected not to cooperate with study procedures. * allergy to plaster or silicone. * patients admitted for palliative care only (i.e. no active treatment). * patients previously enrolled in the studies ward-copd (h-18026653) or ward-surgery (h-17033535). * inability to give informed consent.
suprascapular neuropathy in the setting of rotator cuff tears: results of arthroscopic treatment

Conditions: Entrapment Neuropathy; Rotator Cuff Tear

Summary: aim of this prospective double blind randomized clinical trial is to understand the correlation of suprascapular neuropathy in the setting of large and massive tears of the shoulder rotator cuff and to investigate whether arthroscopic dissection of the superior transverse scapular ligament is positively related to the improvement of this neuropathy.

the suprascapular nerve originates from the upper trunk of the brachial plexus with participation from the a5 and a6 spinal nerve roots and occasionally from the a4 root. it is treading behind the clavicle and to the upper border of the scapula and then enters through the scapular notch of the shoulder and below the transverse superior transverse ligament to the rear surface of the scapula. this entry point is an important factor of pressure and surgical dissection of the ligament enlarges the space through which the nerve travels. the rotator cuff consists of the tendons of subscapularis, supraspinatus , infraspinatus and minor teres muscles. cadaveric studies have shown that tears in the cuff , particularly massive ruptures a gap more than 5cm, change the path of the suprascapular nerve and create conditions that pressure. until now, there are no prospective studies that compare the improvement of suprascapular neuropathy after arthroscopic dissection of the superior transverse scapular ligament in patients with rotator cuff tears , or that study the degree of neuropathy compared with the extent of the rupture .

Eligibility criteria:
inclusion criteria: - large of massive repairable rotator cuff tears combined suprascapular neuropathy exclusion criteria: * suprascapular neuropathy of another cause (eg. brachial plexus neuropathy) * other surgery at the same shoulder region

Keywords: suprascapular nerve rotator cuff tear suprascapular neuropathy superior transverse scapular ligament
a study of step-up in bronchial asthma as a new end point in asthma control (surfe)

Conditions: Bronchial Asthma

Summary: the goal of this observational study is to learn about the frequency needed for stepping-up treatment in patients with mild and moderate bronchial asthma. the main questions this study aims to answer are: * what is the frequency and duration in which patients of asthma need to step up their treatment? * can the criteria described in this study be applied and validated to test need for step up of asthma treatment? participants will follow the treatment they are already receiving according to established guidelines and will be asked for regular visits for examination and spirometry. they will record symptoms score, each time they use the prescribed rescu inhaler, and morning and evening peak expiratory flow.


Eligibility criteria:
inclusion criteria: 1. able to give written informed consent. 2. age above 12 years. 3. ability to use study inhalers correctly, use e-diary, and comply with study procedures and visits. 4. confirmed diagnosis of mild or moderate asthma asthma (based on gina defined asthma control on a maximum of maintenance low dose ics/laba combination). 5. pre-bronchodilator ≥fev1 60%. 6. reversibility test ≥12% or 200 ml from baseline. 7. non-smoker. 8. for female subjects, non-pregnant and administer efficient contraception if in childbearing period. exclusion criteria: 1. severe asthma exacerbation in last 3 months. 2. use of any systemic corticosteroids in last 12 weeks. 3. use of depot systemic steroids in last 12 weeks. 4. any concurrent respiratory disease as bronchiectasis, copd, lung fibrosis, ... 5. current or known history of tuberculosis in any organ. 6. current malignancy or any history of malignant disease for the past 5 years. 7. subjects receiving any medications with known drug interaction with study medications. 8. use of beta-blockers including eye drops. 9. any significant concurrent disease as cardiac, hepatic, renal, ... 10. current or history of alcohol or drug abuse. 11. current or history of significant psychiatric disease. 12. current or history of significant immunodefieciency. 13. history of receiving any biological therapy for asthma for the last 3 years or currently eligible for any biological therapy for asthma. 14. subjects under any immuno-modulating therapy including biological therapy for any other indication. subjects may be allowed to participate after 5 times half-live of the concerned drug. 15. any known allergy or contraindication to any of the study medications.

Keywords: bronchial asthma asthma step-up asthma step-down asthma exacerbation mild asthma moderate asthma
treatment of pediatric supracondylar humeral fractures with novel kirschner wire fixation devices

Conditions: Supracondylar Humerus Fracture

Summary: a novel k-wire external fixation device was developed by the investigators. the k-wires can be connected by the device. after connection, the structure of the k-wires is transformed to an external skeletal fixator. therefore, the k-wires are stabilized and unable to migrate independently. the stability of fracture fixation is better in patient with this k-wire external fixation device. the purposes of this study are to optimize the k-wire external fixation device and test its function in real clinical practice.

supracondylar humeral fractures are the most common elbow fractures in children. closed reduction and internal fixation using percutaneous kirschner wires (k-wires) are widely recommended for gartland type ii and iii fractures. after percutaneous pinning, the k-wires are bent at the skin edge and cut. the cutoff point is about 1 cm outside of the skin. the diameters of the k-wires are between 1.5-3.0 mm. the surface of the k-wire is smooth. therefore, the k-wires are easy to rotation and migration. proximal migration or rotation of a k-wire could injure the skin. distal migration of a k-wire could result in loss of reduction and fixation. therefore, stabilization of the k-wires is important. a novel k-wire external fixation device was developed by the investigators. the k-wires can be connected by the device. after connection, the structure of the k-wires is transformed to an external skeletal fixator. therefore, the k-wires are stabilized and unable to migrate independently. the stability of fracture fixation is better in patient with this k-wire external fixation device. the investigators got a one-year grant from the ministry of science and technology in taiwan last year. the preliminary data revealed that the torque and torsional stiffness with the k-wire external fixation device was greater than traditional pinning. the purposes of this study are to optimize the k-wire external fixation device and test its function in real clinical practice.

Eligibility criteria:
inclusion criteria: * pediatric supracondylar humeral fracture * patients receiving closed reduction and percutaneous pinning exclusion criteria: * open fracture * open reduction * neurovascular exploration

Keywords: supracondylar humerus fracture kirschner wire
study of genetic and cellular immunological parameters predictive of disease-free survival in patients with metastatic cancer

Conditions: Metastatic Cancer

Summary: the aim of this study is to characterize the genetic and cellular immunological parameters of metastatic digestive cancer patients having short and long responses to chemotherapy.


Eligibility criteria:
inclusion criteria: for all patients: * signed written informed consent for cohort a: * patient with metastatic colorectal cancer with first-line therapy by chemotherapy +/- surgery and with a disease-free survival \> or = at 20 months * ct-scan realized in the previous 4 weeks and showing no progression according to the recist criteria v1.1 for cohort b: * patient treated for metastatic colorectal cancer and chemotherapy responder (obtention of an objective response according to the recist criteria v1.1 in first-line therapy), with a disease-free survival \< 10 months (disease progression must be confirmed by ct scan evaluation according to recist v1.1 criteria) for cohort c: * patients with no metastatic rectum cancer in complete remission after chemotherapy and/or radiotherapy for cohort d: * patients with metastatic or locally advanced cancer in complete remission after treatment, non eligible in the other cohorts exclusion criteria: for all patients: * patient with any medical or psychiatric condition or disease which would make the patient inappropriate for entry into this study * patient with a neurodegenerative disease * patient under guardianship, curator or under the protection of justice
motivational enhancement to improve treatment engagement and outcome in subjects seeking treatment for substance abuse - 1

Conditions: Substance-Related Disorders

Summary: the purpose of this study is to evaluate the therapeutic usefulness of incorporating motivational enhancement treatment into the standard drug abuse treatment entry process of community treatment programs on improving treatment engagement, retention, and outcome.

participants seeking treatment at the participating ctps will be randomly assigned to either "standard" or "met/mi" treatment, with a 1- and 3-month follow-up. primary outcome measures will include (1) treatment retention (e.g., number of sessions/weeks completed, the rate of patients completing 3 or more subsequent sessions, and (2) substance use (e.g., urinalyses, days of opioid, cocaine, marijuana, alcohol use, rates of abstinence). secondary outcomes will include motivation, psychosocial functioning, hiv risk behaviors, treatment utilization, and patient satisfaction. process assessments will include measures of the working alliance as well as therapist adherence/competence ratings which will evaluate how effectively met/mi was implemented. participating ctps will implement one of two independent protocols, depending on which is the best suited or feasible for the intake procedures at their clinic. thus, following an invitation to participate, explanation of the study, and provision of informed consent, patients would complete a brief assessment battery followed by either: 1) random assignment to 3 individual sessions of standard treatment (treatment as usual) at the program versus 3 individual sessions of met. or 2) random assignment to 1 individual standard assessment/evaluation session.

Eligibility criteria:
inclusion criteria: individuals will be eligible for the protocol who: * are seeking outpatient treatment for any substance use disorder * are willing to participate in the protocol (e.g., to be randomized to treatment, be contacted for follow-up assessment, to have their sessions audiotaped) * are able to understand and provide written informed consent exclusion criteria: individuals will be excluded who: * are not sufficiently medically or psychiatrically stable to participate in outpatient treatment * are seeking detoxification only, methadone maintenance treatment or residential inpatient treatment

Keywords: substance use disorder
interest of concentrations in meconium of buprenorphine and methadone as a prognostic factor of nas outcome

Conditions: Neonatal Abstinence Syndrome

Summary: the aim of this study is to characterize the interest of concentrations in meconium of drugs used for treatment of pregnant opioid-dependent woman as a prognostic factor of time, severity and duration of neonatal abstinence syndrome (nas). 43 women treated with buprenorphine, 49 with methadone, and their newborns, were included. nas is assessed by lipsitz scale. buprenorphine, norbuprenorphine, methadone, eddp and morphine are quantified in meconium (one collected immediately after birth, another for 24 to 48 h) by a liquid chromatography-tandem mass spectrometry (lc-ms/ms) method, developed and validated for this study.


Eligibility criteria:
inclusion criteria: * aged over 18 years * pregnant women * having agreed to participate in the study after information * under opioid replacement therapy during pregnancy, in combination or not with other psychotropic drugs or legal or illegal substances. * delivery after more than 34 weeks of amenorrhea exclusion criteria: * pregnant women not receiving substitution treatment (methadone or buprenorphine). * patient under substitution treatment delivering before 34 weeks of amenorrhea * patient aged under 18 yrs old * patient unable to understand the study (mental deficiency, impairment of consciousness, not french) or not accepting to answer the questionnaires. * severe malformation syndrome or chromosomal abnormality in newborn discovered during pregnancy. * mother's death or newborn's death

Keywords: meconium concentration buprenorphine methadone pregnant liquid chromatography-tandem mass spectrometry opioid-dependant woman
docetaxel and carboplatin followed by oral capecitabine, docetaxel and radiation for esophageal cancer

Conditions: Esophageal Neoplasms

Summary: the primary objective is to determine the maximum tolerated dose of oral capecitabine, in combination with fixed doses of weekly docetaxel, and concurrent thoracic radiation for the treatment of patients with clinical stage ii-iii cancer of the esophagus and gastroesophageal junction.

this dose-ranging trial is designed to establish the phase ii dose of capecitabine that can safely be given with docetaxel and radiation therapy for the treatment of patients with cancer of the esophagus and gastroesophageal junction. the docetaxel dose of 15 mg/m2/week, 5-fluorouracil dose of 200 mg/m2/week, and 50.4 gy of thoracic radiation has been found to be the recommended doses from our initial phase i trial (dms d9724). the phase i study has been modified in an attempt to improve the pathological complete response rate by increasing the 5-fluorouracil exposure during thoracic radiation by replacing it with oral capecitabine. capecitabine generates 5-fluorouracil selectively in tumor cells. this sequentially designed study of eus staging, molecular analysis, neoadjuvant chemotherapy, concomitant chemotherapy and radiation, and surgical resection continues to expand our collaborative experience at dartmouth hitchcock in the treatment of cancer of the esophagus and gastroesophageal junction.

Eligibility criteria:
inclusion criteria: * esophageal or gastroesophageal junction cancer that is locally advanced and surgically resectable (stage ii or iii disease). * no prior therapy. * adequate organ function. exclusion criteria: * evidence of metastasis (celiac axis lymph nodes are allowed). * cervical esophageal tumors. * peripheral or auditory neuropathy grade \>= 2.

Keywords: esophageal cancer trimodality capecitabine xeloda gastro-esophageal neoplasm carcinoma of the esophagus